R. W. Atchison, B. C. Casto, and W. M. Hammon, Adenovirus-Associated Defective Virus Particles, Science, vol.149, issue.3685, pp.754-756, 1965.
DOI : 10.1126/science.149.3685.754

S. Boutin, V. Monteilhet, P. Veron, C. Leborgne, O. Benveniste et al., Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors, Human Gene Therapy, vol.21, issue.6, pp.704-712, 2010.
DOI : 10.1089/hum.2009.182

R. Calcedo, L. H. Vandenberghe, G. Gao, J. Lin, W. et al., Worldwide Epidemiology of Neutralizing Antibodies to Adeno???Associated Viruses, The Journal of Infectious Diseases, vol.2, issue.3, pp.381-390, 2009.
DOI : 10.1126/science.1154258

S. Russell, J. Bennett, J. A. Wellman, D. C. Chung, Z. F. Yu et al., Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial, The Lancet, vol.390, issue.10097, pp.849-860, 2017.
DOI : 10.1016/S0140-6736(17)31868-8

A. C. Nathwani, U. M. Reiss, E. G. Tuddenham, C. Rosales, P. Chowdary et al., Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B, New England Journal of Medicine, vol.371, issue.21, 1994.
DOI : 10.1056/NEJMoa1407309

URL : http://europepmc.org/articles/pmc4278802?pdf=render

T. Matsushita, S. Elliger, C. Elliger, G. Podsakoff, L. Villarreal et al., Adeno-associated virus vectors can be efficiently produced without helper virus, Gene Therapy, vol.5, issue.7, pp.938-945, 1998.
DOI : 10.1038/sj.gt.3300680

URL : http://www.nature.com/gt/journal/v5/n7/pdf/3300680a.pdf

R. M. Kotin and R. O. Snyder, Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines, Human Gene Therapy, vol.28, issue.4, pp.350-360, 2017.
DOI : 10.1089/hum.2017.042

D. L. Thomas, L. Wang, J. Niamke, J. Liu, W. Kang et al., Scalable Recombinant Adeno-Associated Virus Production Using Recombinant Herpes Simplex Virus Type 1 Coinfection of Suspension-Adapted Mammalian Cells, Human Gene Therapy, vol.20, issue.8, pp.861-870, 2009.
DOI : 10.1089/hum.2009.004

L. Adamson-small, M. Potter, B. J. Byrne, C. , and N. , Sodium Chloride Enhances Recombinant Adeno-Associated Virus Production in a Serum-Free Suspension Manufacturing Platform Using the Herpes Simplex Virus System, Human Gene Therapy Methods, vol.28, issue.1, pp.1-14, 2017.
DOI : 10.1089/hgtb.2016.151

B. A. Thorne, R. K. Takeya, and R. W. Peluso, Manufacturing Recombinant Adeno-Associated Viral Vectors from Producer Cell Clones, Human Gene Therapy, vol.20, issue.7, pp.707-714, 2009.
DOI : 10.1089/hum.2009.070

J. Martin, A. Frederick, Y. Luo, R. Jackson, M. Joubert et al., Generation and Characterization of Adeno-Associated Virus Producer Cell Lines for Research and Preclinical Vector Production, Human Gene Therapy Methods, vol.24, issue.4, pp.253-269, 2013.
DOI : 10.1089/hgtb.2013.046

D. K. Gavin, FDA statement regarding the use of adeno-associated virus reference standard materials. Hum, Gene Ther. Methods, vol.26, issue.3, 2015.
DOI : 10.1089/hgtb.2015.1501

Z. Zen, Y. Espinoza, T. Bleu, J. M. Sommer, W. et al., Infectious Titer Assay for Adeno-Associated Virus Vectors with Sensitivity Sufficient to Detect Single Infectious Events, Human Gene Therapy, vol.15, issue.7, pp.709-715, 2004.
DOI : 10.1089/1043034041361262

A. Salvetti, S. Orève, G. Chadeuf, D. Favre, Y. Cherel et al., Factors Influencing Recombinant Adeno-Associated Virus Production, Human Gene Therapy, vol.9, issue.5, pp.695-706, 1998.
DOI : 10.1089/hum.1998.9.5-695

S. Zolotukhin, B. J. Byrne, E. Mason, I. Zolotukhin, M. Potter et al., Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield, Gene Therapy, vol.70, issue.6, 1999.
DOI : 10.1089/hum.1997.8.16-1911

URL : http://www.nature.com/gt/journal/v6/n6/pdf/3300938a.pdf

, Gene Ther, vol.6, pp.973-985

N. Zeltner, E. Kohlbrenner, N. Clément, T. Weber, and R. M. Linden, Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors, Gene Therapy, vol.22, issue.7, pp.872-879, 2010.
DOI : 10.1038/gt.2010.27

A. Girod, C. E. Wobus, Z. Zádori, M. Ried, K. Leike et al., The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity, Journal of General Virology, vol.1, issue.5, pp.973-978, 2002.
DOI : 10.1016/S1534-5807(01)00031-4

J. S. Johnson, C. Li, N. Diprimio, M. S. Weinberg, T. J. Mccown et al., Mutagenesis of Adeno-Associated Virus Type 2 Capsid Protein VP1 Uncovers New Roles for Basic Amino Acids in Trafficking and Cell-Specific Transduction, Journal of Virology, vol.84, issue.17, pp.8888-8902, 2010.
DOI : 10.1128/JVI.00687-10

R. Popa-wagner, M. Porwal, M. Kann, M. Reuss, M. Weimer et al., Impact of VP1-Specific Protein Sequence Motifs on Adeno-Associated Virus Type 2 Intracellular Trafficking and Nuclear Entry, Journal of Virology, vol.86, issue.17, pp.9163-9174, 2012.
DOI : 10.1128/JVI.00282-12

E. Ayuso, V. Blouin, M. Lock, S. Mcgorray, X. Leon et al., Manufacturing and Characterization of a Recombinant Adeno-Associated Virus Type 8 Reference Standard Material, Human Gene Therapy, vol.25, issue.11, 2014.
DOI : 10.1089/hum.2014.057

URL : https://hal.archives-ouvertes.fr/inserm-01847281

, Gene Ther, vol.25, pp.977-987

B. L. Gurda, C. Raupp, R. Popa-wagner, M. Naumer, N. H. Olson et al., Mapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8, Journal of Virology, vol.86, issue.15, pp.7739-7751, 2012.
DOI : 10.1128/JVI.00218-12

A. Wistuba, S. Weger, A. Kern, and J. A. Kleinschmidt, Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins, J. Virol, vol.69, pp.5311-5319, 1995.

S. Pacouret, M. Bouzelha, R. Shelke, E. Andres-mateos, R. Xiao et al., AAV-ID: A Rapid and Robust Assay for Batch-to-Batch Consistency Evaluation of AAV Preparations, Molecular Therapy, vol.25, issue.6, pp.1375-1386, 2017.
DOI : 10.1016/j.ymthe.2017.04.001

URL : https://hal.archives-ouvertes.fr/inserm-01798869

D. Kuck, A. Kern, and J. A. Kleinschmidt, Development of AAV serotype-specific ELISAs using novel monoclonal antibodies, Journal of Virological Methods, vol.140, issue.1-2, pp.17-24, 2007.
DOI : 10.1016/j.jviromet.2006.10.005

P. J. Xiao and R. J. Samulski, Cytoplasmic Trafficking, Endosomal Escape, and Perinuclear Accumulation of Adeno-Associated Virus Type 2 Particles Are Facilitated by Microtubule Network, Journal of Virology, vol.86, issue.19, pp.10462-10473, 2012.
DOI : 10.1128/JVI.00935-12

K. R. Clark, F. Voulgaropoulou, D. M. Fraley, J. , and P. R. , Cell Lines for the Production of Recombinant Adeno-Associated Virus, Human Gene Therapy, vol.6, issue.10, pp.1329-1341, 1995.
DOI : 10.1089/hum.1995.6.10-1329

G. Chadeuf, D. Favre, J. Tessier, N. Provost, P. Nony et al., Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome, The Journal of Gene Medicine, vol.49, issue.4, pp.260-268, 2000.
DOI : 10.1128/MCB.14.2.1333

M. Lock, S. Mcgorray, A. Auricchio, E. Ayuso, E. J. Beecham et al., Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum. Gene Ther, pp.1273-1285, 2010.

P. Seth, M. Rosenfeld, J. Higginbotham, C. , and R. G. , Mechanism of enhancement of DNA expression consequent to cointernalization of a replicationdeficient adenovirus and unmodified plasmid DNA, J. Virol, vol.68, pp.933-940, 1994.

R. Awedikian, A. François, M. Guilbaud, P. Moullier, and A. Salvetti, Intracellular route and biological activity of exogenously delivered Rep proteins from the adeno-associated virus type 2, Virology, vol.335, issue.2, pp.252-263, 2005.
DOI : 10.1016/j.virol.2005.02.024

P. Nony, G. Chadeuf, J. Tessier, P. Moullier, and A. Salvetti, Evidence for Packaging of rep-cap Sequences into Adeno-Associated Virus (AAV) Type 2 Capsids in the Absence of Inverted Terminal Repeats: a Model for Generation of rep-Positive AAV Particles, Journal of Virology, vol.77, issue.1, pp.776-781, 2003.
DOI : 10.1128/JVI.77.1.776-781.2003

D. Grimm, A. Kern, K. Rittner, and J. A. Kleinschmidt, Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors, Human Gene Therapy, vol.9, issue.18, pp.2745-2760, 1998.
DOI : 10.1089/hum.1998.9.18-2745

F. K. Ferrari, T. Samulski, T. Shenk, and R. J. Samulski, Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors, J. Virol, vol.70, pp.3227-3234, 1996.

M. Salganik, F. Aydemir, H. J. Nam, R. Mckenna, M. Agbandje-mckenna et al., Adeno-Associated Virus Capsid Proteins May Play a Role in Transcription and Second-Strand Synthesis of Recombinant Genomes, Journal of Virology, vol.88, issue.2, pp.1071-1079, 2014.
DOI : 10.1128/JVI.02093-13

K. T. Gagnon, L. Li, B. A. Janowski, C. , and D. R. , Analysis of nuclear RNA interference in human cells by subcellular fractionation and Argonaute loading, Nature Protocols, vol.78, issue.9, pp.2045-2060, 2014.
DOI : 10.1101/cshperspect.a000539

S. Kronenberg, B. Böttcher, C. W. Von-der-lieth, S. Bleker, and J. A. Kleinschmidt, A Conformational Change in the Adeno-Associated Virus Type 2 Capsid Leads to the Exposure of Hidden VP1 N Termini, Journal of Virology, vol.79, issue.9, pp.5296-5303, 2005.
DOI : 10.1128/JVI.79.9.5296-5303.2005

F. Sonntag, S. Bleker, B. Leuchs, R. Fischer, and J. A. Kleinschmidt, Adeno-Associated Virus Type 2 Capsids with Externalized VP1/VP2 Trafficking Domains Are Generated prior to Passage through the Cytoplasm and Are Maintained until Uncoating Occurs in the Nucleus, Journal of Virology, vol.80, issue.22, pp.11040-11054, 2006.
DOI : 10.1128/JVI.01056-06

H. J. Nam, B. L. Gurda, R. Mckenna, M. Potter, B. Byrne et al., Structural Studies of Adeno-Associated Virus Serotype 8 Capsid Transitions Associated with Endosomal Trafficking, Journal of Virology, vol.85, issue.22, pp.11791-11799, 2011.
DOI : 10.1128/JVI.05305-11

F. Mingozzi and K. A. High, Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges, Nature Reviews Genetics, vol.6, issue.5, pp.341-355, 2011.
DOI : 10.1002/jgm.554

M. Mietzsch, S. Grasse, C. Zurawski, S. Weger, A. Bennett et al., OneBac: Platform for Scalable and High-Titer Production of Adeno-Associated Virus Serotype 1???12 Vectors for Gene Therapy, Human Gene Therapy, vol.25, issue.3, pp.212-222, 2014.
DOI : 10.1089/hum.2013.184

M. Mietzsch, V. Casteleyn, S. Weger, S. Zolotukhin, and R. Heilbronn, , 2015.

, OneBac 2.0: Sf9 Cell Lines for Production of AAV5 Vectors with Enhanced Infectivity and Minimal Encapsidation of Foreign DNA. Hum, Gene Ther, vol.26, pp.688-697

M. Urabe, T. Nakakura, K. Q. Xin, Y. Obara, H. Mizukami et al., Scalable Generation of High-Titer Recombinant Adeno-Associated Virus Type 5 in Insect Cells, Journal of Virology, vol.80, issue.4, pp.1874-1885, 2006.
DOI : 10.1128/JVI.80.4.1874-1885.2006

B. L. Ellis, M. L. Hirsch, J. C. Barker, J. P. Connelly, R. J. Steininger et al., A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype, Virology Journal, vol.10, issue.1, p.74, 2013.
DOI : 10.1210/me.2002-0333

C. Burger, O. S. Gorbatyuk, M. J. Velardo, C. S. Peden, P. Williams et al., Recombinant AAV Viral Vectors Pseudotyped with Viral Capsids from Serotypes 1, 2, and 5 Display Differential Efficiency and Cell Tropism after Delivery to Different Regions of the Central Nervous System, Molecular Therapy, vol.10, issue.2, pp.302-317, 2004.
DOI : 10.1016/j.ymthe.2004.05.024

R. J. Samulski, L. S. Chang, and T. Shenk, A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication, J. Virol, vol.61, pp.3096-3101, 1987.

G. P. Gao, M. R. Alvira, L. Wang, R. Calcedo, J. Johnston et al., Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc. Natl. Acad. Sci. USA 99, pp.11854-11859, 2002.
DOI : 10.1038/sj.gt.3300994

F. Sonntag, K. Köther, K. Schmidt, M. Weghofer, C. Raupp et al., The Assembly-Activating Protein Promotes Capsid Assembly of Different Adeno-Associated Virus Serotypes, Journal of Virology, vol.85, issue.23, pp.12686-12697, 2011.
DOI : 10.1128/JVI.05359-11

B. Thimmappaya, C. Weinberger, R. J. Schneider, and T. Shenk, Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection, Cell, vol.31, issue.3, pp.543-551, 1982.
DOI : 10.1016/0092-8674(82)90310-5